Gastrointestinal (GI) disorders frequently occur after allogeneic stem cell transplantation (allo-SCT), infections and GvHD represent the most frequent events. They develop as a consequence of tissue damage, particularly in the GI tract, induced by the conditioning regimen. Release of damage-associated molecular pattern molecules and pathogen-associated molecular pattern molecules after conditioning induces the activation of the innate and adaptive immune responses leading to GI GvHD. Despite sharing common pathophysiology pathways with GI GvHD, inflammatory bowel disease (IBD) has been occasionally described after allo-SCT.
We report here a case of IBD occurring 1 year after allo-SCT in the context of post-transplant immune dysfunction.
A 57-year-old Caucasian woman without medical history was diagnosed in September 2011 with myelodysplasia/myelofibrosis disease. Bone marrow biopsy showed 19.5% blasts with a normal karyotype. She received one course of induction chemotherapy with idarubicin and cytosine-arabinoside leading to CR. She then received two consolidation courses based on the same schedule. She proceeded to undergo allo-SCT from an HLA-identical sister (HLA A*01-02/B*08-57/C*06-07/DRB1*03-07/DQB1*02-03). Conditioning regimen included fludarabine 30 mg/m 2 /day for 5 days, IV busulfan 3.2 mg/kg/day for 3 days and thymoglobulin 2.5 mg/kg/day for 2 days. The PBSC graft contained 4.7 × 10 6 CD34 + and 26.1 × 10 7 CD3 + cells/kg of recipient's body weight. Post-transplant GvHD prophylaxis consisted of cyclosporine-A (CsA).
After transplantation, she presented two episodes of CMV reactivation on day 30 and at 5 months, both treated by valgancyclovir. By day 40, EBV reactivation was treated by two weekly courses of rituximab at 375 mg/m 2 /day. At day 100, there was full donor chimerism in whole blood and in the CD3 + cell fraction, and she was in complete cytologic remission.
In the absence of acute GvHD, CsA was tapered between 2 and 3 months post transplantation. At 4 months, she developed cutaneous grade II acute GvHD treated with CsA and systemic oral steroids at 2 mg/kg/day. She had no GI symptoms at that time. At 7 months, steroids could be stopped but CsA was maintained because of the persistence of histologically proven skin manifestations of chronic GvHD. These consisted in follicular lichen papules of the face and the axillae, as well as lichenoid alopecic plaques of the scalp and the eyebrows. These lesions were treated with topical steroids and topical tacrolimus. She also presented dry eye syndrome treated with eye drops (carmellose sodium 1%).
At 1 year and 4 months after transplantation, although different types of cutaneous lesions consisting of 'psoriasis-like' umbilical and peri-anal lesions developed, she presented diarrhea, abdominal pain and with 5-kg weight loss. Diarrhea consisted of 2-3 soft stools per day without fever or mucous stools. A colonoscopy was performed up to right colon, which showed diffuse edematous and congestive lesions consistent with colitis. Biopsies showed inflammation of the mucosa with crypt distortion and irregular mucosal surface (Figure 1 ). Crypt abscesses were sometimes seen (Figure 2 ). There was no sign of GvHD and, especially, no apoptotic criteria, gland destruction or submucosal fibrosis. There was also no evidence of infectious agents, particularly of CMV. The final diagnosis was IBD and, more likely, ulcerative colitis, given the absence of mucin depletion and the presence of crypt abcesses and diffuse inflammation. She was treated with oral budesonide and mesalazine with rapid clinical improvement. One year later, clinical symptoms completely resolved and she recovered normal weight under maintenance treatment with mesalazine.
Patients often experience diarrhea after allo-SCT. The diagnosis of GvHD must be invoked but it is not the only possibility. In these cases, the anatomopathological findings have an important place. Here we report the case of a female patient who presented an association of immune dysfunction symptoms after allo-SCT, with dry eye syndrome, psoriasis-like skin lesions and IBD. These manifestations occurred while she was receiving immunosuppressive treatment for chronic GvHD. There is only one similar case in the literature. 1 Sonwalkar et al. 1 reported a case of Crohn's colitis occurring after myeloablative conditioning allo-SCT for Hodgkin lymphoma.
IBD is a multifactorial disease with environmental, microbial, immunologic and genetic factors. It is now well established that dysfunctions in genes involved in host-microbe interactions have an important role in the development of these diseases. 2, 3 However, although many genetic polymorphisms are associated with IBD on genes such as NOD2, MICB, IBD 1 or 3, no causal mutations have been pointed out. 4, 5 Since the discovery of these mutations in susceptibility genes, many authors have raised the hypothesis of adoptive transfer of genetic susceptibility in IBD, 1, 4 especially after transplantation. The onset of IBD after transplantation has been more frequently described in the field of solid organs such as liver. 6 Nevertheless, the reported cases were recipients with history of primary sclerosing cholangitis or autoimmune hepatitis, which are by themselves associated with IBD. 7 In the study by Sonwalkar et al., the donor, but not the recipient, exhibited a 5′UTR polymorphism of NOD2/CARD15 that might be associated with Crohn's disease. There were also haplotype mismatches between the donor and the recipient at the IBD3 locus. These genetic abnormalities highlight the possibility of adoptive gene transfer.
We performed detailed genetic analysis of the NOD2 locus in our case. We did not find the NOD2 polymorphisms rs2066844, rs2066845 or rs2066847, which are the most frequently associated polymorphisms with IBD, in the donor or the recipient. However, we did not analyze all susceptibility genes described in the literature.
In the majority of case reports of post-transplantation IBD, the donor had no signs of this disease. This highlights the fact that other factors have a role in the IBD onset after transplantation, such as alterations of the intestinal microbiota after the conditioning regimen, antibiotics, immunosuppressive treatment or interaction with the non myeloid cells and particularly epithelial cells. 1, 2 Stabilization or even remission of IBD after allo-SCT has been well described. 8, 9 However, its onset in a recipient who had no signs before the procedure is rare. These reports allow us to better explore the complex physiopathology of this disease, and raise the question of a systematic screening of the donors for any gut symptoms. 
